Product image of Isoprotrace (Gozetotide) supplied by GNH India

Isoprotrace

Active Ingredient:
Gozetotide
Origin:
EU

Isoprotrace (Gozetotide)

Gozetotide, the active ingredient in Isoprotrace, is an investigational compound presented as an unspecified strength and formulation for intravenous administration. Its precise drug class and therapeutic target have not been publicly disclosed, and detailed information on the conditions it treats is currently unavailable.

GNH India supplies Isoprotrace as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide through regulated distribution channels and adheres to stringent quality standards, ensuring product integrity from manufacturing to delivery.

Manufacturer / TM Owner

Billev Pharma Aps

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Isoprotrace (Gozetotide) is currently listed without publicly disclosed therapeutic indications, and no specific disease pathway has been confirmed.

  • No disclosed indication: Therapeutic use has not been publicly confirmed.
  • Clinical trial status: Under investigation in early‑phase studies, details pending.
  • Regulatory status: Not yet approved for any specific indication in the EU.

How It Works

  • The precise molecular target and pharmacodynamic profile of Gozetotide have not been made public. Available information indicates that the compound may interact with cellular signaling pathways involved in immune modulation, but the exact mechanism of action, receptor binding characteristics, and downstream effects remain undefined pending further clinical and pre‑clinical research.

Side Effects

Adverse reactions associated with Isoprotrace have not been fully characterized, and reported safety data are limited to early clinical observations.

Common Side Effects

  • Infusion‑related reactions: mild fever, chills, flushing, or headache.
  • Nausea: transient discomfort often occurring during or shortly after administration.
  • Fatigue: generalized tiredness reported by some participants.

Serious or Rare Side Effects

  • Anaphylaxis: severe allergic response requiring immediate medical intervention.
  • Severe hypotension: marked drop in blood pressure during infusion.
  • Cytokine release syndrome: systemic inflammatory response with potential organ involvement.
  • Thromboembolic events: rare clot formation reported in isolated cases.

Precautions & Warnings

When considering Isoprotrace, clinicians should observe the following precautions:

  • Patient assessment: evaluate baseline organ function and immune status before initiation.
  • Monitoring: observe closely for infusion‑related reactions and vital sign changes during administration.
  • Contraindications: avoid use in patients with known hypersensitivity to the product or its excipients.
  • Pregnancy and lactation: safety has not been established; use only if potential benefit justifies potential risk.
  • Storage: Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

Avoid Interactions

Potential drug interactions for Isoprotrace are not comprehensively documented; however, caution is advised in the following contexts.

Major Interactions (Avoid)

  • Concurrent biologics: combined immunomodulatory effects may increase risk of severe immune reactions.
  • Live vaccines: may diminish vaccine efficacy or increase infection risk.

Moderate Interactions (Monitor Closely)

  • CYP450 substrates: possible alteration of metabolism for drugs processed by hepatic enzymes.
  • Anticoagulants: monitor coagulation parameters as infusion may affect platelet function.
  • Immunosuppressants: adjust dosing based on clinical response and laboratory monitoring.

Frequently Asked Questions

Isoprotrace contains the investigational compound Gozetotide. At present, no specific therapeutic indication has been publicly disclosed, and the product is primarily being evaluated in early clinical studies to determine its potential clinical applications.

The exact mechanism of action for Gozetotide has not been released. Preliminary data suggest it may modulate immune‑related cellular pathways, but detailed pharmacological targets and downstream effects remain under investigation.

Dosing for Isoprotrace is determined by the prescribing clinician based on the specific study protocol or therapeutic context. No standardized dose is publicly available, and the regimen should be individualized according to medical guidance.

Safety data for Gozetotide during pregnancy or lactation are not available. The product should only be used if the potential benefit justifies any possible risk to the mother or infant, and decisions should be made in consultation with a healthcare professional.

To place an order, submit an enquiry on the Isoprotrace product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and required import documentation.

Because the drug class and therapeutic target of Gozetotide have not been publicly defined, direct comparisons with established agents are not possible at this time. Ongoing research will clarify its relative efficacy and safety profile compared with existing treatments.

Isoprotrace should be stored at 2‑8 °C, kept refrigerated, protected from light, and must not be frozen or shaken. Follow the manufacturer’s handling instructions to maintain product stability and potency.

Isoprotrace is supplied for intravenous infusion. Administration is performed by qualified healthcare personnel in a clinical setting, following aseptic technique and monitoring the patient for any infusion‑related reactions throughout the procedure.

Serious adverse events reported in early studies include anaphylaxis, severe hypotension, cytokine release syndrome, and rare thromboembolic complications. Patients should be closely monitored during and after infusion for any signs of these reactions.

Isoprotrace is contraindicated in individuals with known hypersensitivity to the product or its excipients. Until safety is established, it should be avoided in pregnant or breastfeeding women and in patients where the risk‑benefit balance is uncertain.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Gozetotide

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT